Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SEC Filings
FORM TYPE RECEIVED PERIOD END DATE REPORT
8-K 11/04/2021 11/04/2021 PDFRTFHTMLXLS
4 10/20/2021 10/18/2021 PDFRTFHTMLXLS
dis was to slam dunk $mrna Arbutus Biopharma Corporation (ABUS)'
$ABUS vs $MRNA #2 Photo of Tim Brown Tim BrownOctober 28, 2021
© 2021 InvestorsHub.com, Inc.
https://dcdirtylaundry.com/covid-19-moderna-gets-its-miracle/
COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else, and why did they later claim that their vaccine being tested in NIH trials was different than their commercial candidate?
In late 2019, the biopharmaceutical company Moderna was facing a series of challenges that not only threatened its ability to ever take a product to market, and thus turn a profit, but its very existence as a company. There were multiple warning signs that Moderna was essentially another Theranos-style fraud, with many of these signs growing in frequency and severity as the decade drew to a close. Part I of this three-part series explored the disastrous circumstances in which Moderna found itself at that time, with the company’s salvation hinging on the hope of a divine miracle, a “Hail Mary” save of sorts, as stated by one former Moderna employee.
While the COVID-19 crisis that emerged in the first part of 2020 can hardly be described as an act of benevolent divine intervention for most, it certainly can be seen that way from Moderna’s perspective. Key issues for the company, including seemingly insurmountable regulatory hurdles and its inability to advance beyond animal trials with its most promising—and profitable—products, were conveniently wiped away, and not a moment too soon. Since January 2020, the value of Moderna’s stock—which had embarked on a steady decline since its IPO—grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine.
Yet, how exactly was Moderna’s “Hail Mary” moment realized, and what were the forces and events that ensured it would make it through the FDA’s emergency use authorization (EUA) process? In examining that question, it becomes quickly apparent that Moderna’s journey of saving grace involved much more than just cutting corners in animal and human trials and federal regulations. Indeed, if we are to believe Moderna executives, it involved supplying formulations for some trial studies that were not the same as their COVID-19 vaccine commercial candidate, despite the data resulting from the former being used to sell Moderna’s vaccine to the public and federal health authorities. Such data was also selectively released at times to align with preplanned stock trades by Moderna executives, turning many of Moderna’s highest-ranking employees into millionaires, and even billionaires, while the COVID-19 crisis meant economic calamity for most Americans.
Not only that, but—as Part II of this three-part series will show, Moderna and a handful of its collaborators at the National Institutes of Health (NIH) seemed to know that Moderna’s miracle had arrived—well before anyone else knew or could have known. Was it really a coincidental mix of “foresight” and “serendipity” that led Moderna and the NIH to plan to develop a COVID-19 vaccine days before the viral sequence was even published and months before a vaccine was even considered necessary for a still unknown disease? If so, why would Moderna—a company clearly on the brink—throw everything into and gamble the entire company on a vaccine project that had no demonstrated need at the time?
The Serendipitous Origins Of Moderna’s COVID-19 Vaccine
When early January 2020 brought news of a novel coronavirus outbreak originating in Wuhan, China, Moderna’s CEO Stéphane Bancel immediately emailed Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, and asked to be sent the genetic sequence for what would become known as SAR-CoV-2, allegedly because media reports on the outbreak “troubled” him. The date of that email varies according to different media reports, though most place it as having been sent on either January 6th or 7th.
A few weeks before Bancel’s email to Graham, Moderna was quickly approaching the end of the line, their desperately needed “Hail Mary” still not having materialized. “We were freaked out about money,” Stephen Hoge would later remember of Moderna’s late 2019 circumstances. Not only were executives “cutting back on research and other expenditures” like never before, but – as STAT News would later report – “cash from investors had stopped pouring in and partnerships with some drug makers had been discontinued. In meetings at Moderna, Bancel emphasized the need to stretch every dollar and employees were told to reduce travel and other expenses, a frugality there were advised would last several years.”
Trending:
Sorry. No data so far.
At the tail end of 2019, Graham was in a very different mood than Bancel, having emailed the leader of the coronavirus team at his NIH lab saying, “Get ready for 2020,” apparently viewing the news out of Wuhan in late 2019 as a harbinger of something significant. He went on, in the days before he was contacted by Bancel, to “run a drill he had been turning over in his mind for years” and called his long-time colleague Jason McLellan “to talk about the game plan” for getting a head start on producing a vaccine the world did not yet know it needed. When Bancel called Graham soon afterward and asked about this new virus, Graham responded that he didn’t know yet but that “they were ready if it turned out to be a coronavirus.” The Washington Post claimed that Graham’s apparent foreknowledge that a coronavirus vaccine would be needed before anyone officially knew what type of disease was circulating in Wuhan was a fortunate mix of “serendipity and foresight.”
pps not responding https://finviz.com/quote.ashx?t=abus major breakdown
$ABUS $MRNA and the patent case is strongly made in this article.
https://dcdirtylaundry.com/covid-19-moderna-gets-its-miracle/
i see no news, time fer ceo to spill da beans 'Arbutus Biopharma Corporation (ABUS)'
i agree wit $abus
ceo needs to spill some beans.
fer da giant $abus
Interesting tweet, but is it correct Company never comments and analysts are afraid or to stupid to ask
https://twitter.com/msp12389/status/1447634114471870468/photo/1
Arbutus Biopharma Co (ABUS)
4.5 ? 0.35 (8.43%)
Volume: 2,365,575 @10/15/21 7:59:51 PM EDT
Bid Ask Day's Range
4.43 4.5 4.02 - 4.18
ABUS Detailed Quote
FRIDAY A.H. WERE BRIGHT PPS, WHAT DOES PRE-MRKET MONDA BRING 'Arbutus Biopharma Corporation (ABUS)'
Arbutus Biopharma Corporation (NASDAQ: ABUS) At Current Prices: Is It Worth Investing In?
https://marketingsentinel.com/2021/10/15/arbutus-biopharma-corporation-nasdaq-abus-at-current-prices-is-it-worth-investing-in/
Linda Haig October 15, 2021 Technologies
During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)’s traded shares were 2.05 million, with the beta value of the company hitting 2.66. At the end of the trading day, the stock’s price was $4.15, reflecting an intraday loss of -0.24% or -$0.01. The 52-week high for the ABUS share is $5.87, that puts it down -41.45 from that peak though still a striking 41.45% gain since the share price plummeted to a 52-week low of $2.43. The company’s market capitalization is $428.28M, and the average intraday trading volume over the past 10 days was 3.76 million shares, and the average trade volume was 2.39 million shares over the past three months.
Arbutus Biopharma Corporation (ABUS) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.40. ABUS has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.24.
Arbutus Biopharma Corporation (NASDAQ:ABUS) trade information
Arbutus Biopharma Corporation (ABUS) registered a -0.24% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.24% in intraday trading to $4.15 this Thursday, 10/14/21, hitting a weekly high. The stock’s 5-day price performance is 1.22%, and it has moved by -1.66% in 30 days. Based on these gigs, the overall price performance for the year is 31.33%. The short interest in Arbutus Biopharma Corporation (NASDAQ:ABUS) is 4.15 million shares and it means that shorts have 3.13 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.00, which implies an increase of 30.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $10.00 respectively. As a result, ABUS is trading at a discount of -140.96% off the target high and 3.61% off the low.
Arbutus Biopharma Corporation (ABUS) estimates and forecasts
Statistics show that Arbutus Biopharma Corporation has outperformed its competitors in share price, compared to the industry in which it operates. Arbutus Biopharma Corporation (ABUS) shares have gone up 35.18% during the last six months, with a year-to-date growth rate more than the industry average at 10.00% against 7.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 11.10% this quarter and then jump 4.30% in the quarter after that. In the rating firms’ projections, revenue will increase 38.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $2.38 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $2.64 million by the end of Dec 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.20%. While earnings are projected to return 65.40% in 2021.
ABUS Dividends
Arbutus Biopharma Corporation is due to release its next quarterly earnings between November 01 and November 05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Major holders
Arbutus Biopharma Corporation insiders own 19.15% of total outstanding shares while institutional holders control 31.66%, with the float percentage being 39.16%. RTW Investments LP is the largest shareholder of the company, while 119 institutions own stock in it. As of Jun 29, 2021, the company held over 5.98 million shares (or 6.03% of all shares), a total value of $18.11 million in shares.
The next largest institutional holding, with 5.84 million shares, is of Blackrock Inc.’s that is approximately 5.88% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $17.68 million.
Also, the Mutual Funds coming in first place with the largest holdings of Arbutus Biopharma Corporation (ABUS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.8 million shares. This amounts to just over 1.82 percent of the company’s overall shares, with a $5.99 million market value. The same data shows that the other fund manager holds slightly less at 1.79 million, or about 1.81% of the stock, which is worth about $5.42 million.
Don't believe so. Because if that was the case, then Moderna would have gone after Genevant for the two patents. 069 and the other patent are owned by Arbutus. Othewise the case would have been Moderna Versus Genevant for the court document.
ABUS still flying at 7:44 pm. Touched 4.70 AH.
upticking a.h. 10-15-2021 Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Co (ABUS)
4.15 ? -0.01 (-0.24%)
Volume: 1,816,655 @10/14/21 3:36:29 PM EDT
Bid Ask Day's Range
4.14 4.15 3.995 - 4.18
ABUS Detailed Quote
JEEZ, that was IP Hawk, at least give him so credit
$ABUS The key issues are standing and the merits invalidating the patents, specifically anticipation and obviousness. Arbutus argued that Moderna didn’t have standing to bring appeals of the IPR Final Decisions. Arbutus argued the Final Decision on the ‘069 patent should stand and the unpatentable claim findings on the ‘435 patent were wrong and should be remanded back to the PTAB. Moderna cross appealed and argued the opposite. The majority of the hearings time was spent arguing the standing issues and I thought Dan and Gaston did an excellent job explaining the positions in detail. The case the parties frequently cited was argued by Dan so he is very familiar with the standing issues.
So what can happen from here? The CAFC panel (Lourie, O'Malley, & Stoll) can issue Rule 36 decisions rubber stamping the PTAB’s findings without writing opinions, which is usually published within 15 business days from the hearing. The panel can write precedential or non-precedential opinions affirming, reversing, remanding, or a combination of all three, which can take anywhere from two to eight months.
Opinions at the CAFC are usually issued between 9:15am through 10:30am EST. Perry Cooper live tweets the decisions as they roll in every single morning. The opinions are published on the CAFC website at 11:00am EST. There is also a sophisticated unknown party(s) that gets the decisions lightning fast and will move the stocks. Watch the share and option volume spike with a stock move +/- 5% and you will usually know the decision is out and who won or lost.
I believe Arbutus is waiting on the results from the appeals before they decide to file any patent litigation lawsuit against Moderna related to their COVID19 vaccines. A win at the PTAB would put them in a very good position to prevail on the validity side and will likely use estoppel to block invalidity arguments. Arbutus was also issued patent 11,141,378 on October 12, 2021, which is a child parent of the ‘069 and ‘435 patent.
My opinion on the outcome from the appeals: ‘069 patent will be affirmed = Arbutus win. ‘435 patent non-precedential affirming the PTAB on the merits with an opinion on standing that doesn’t change the outcome. There is an outside shot the ‘435 appeal will just be rubber stamped Rule 36 affirmed.
Disclosure - I have no position in $ABUS or $MRNA stock or options at this time. I am not a patent attorney.
Second conference in two weeks that the analysts failed to asked them about their IP and infringement. Even when the question is staring them in their face
i don't think so, must do another deal imho Arbutus Biopharma Corporation (ABUS)'
new patent on infringement one
for license
Does this patent go to Genevant?
well new patent given to $abus today yes ah new one dats my pointer
'Arbutus Biopharma Corporation (ABUS)'
read it again again again
what's your point, we know they have a patent. We are in court now trying to figure out if it valid and infringed
Arbutus Biopharma fireside chat at H.C. Wainwright HBV Virtual Conference October 13, 2021 at 1:00 p.m. EST. Looking forward to some type of update on pipelines possibly other news by then.
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-participate-october-investor-conferences
thank you $ABUS What To Watch With ABUS Stock This Week
This week ABUS stock will be in focus as it presents at another conference.
Following last week’s events, investors may have October 13 on their calendars right now.
This is when management presents at the H.C. Wainwright Hepatitis B Virus.
ABUS: A look at the biopharmas developing new treatments for liver diseases
https://seekingalpha.com/news/3750999-a-look-at-the-biopharmas-developing-new-treatments-for-liver-diseases?utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+News+Smart
YES APPEAL, I THINK IT DOESN'T OVERRULES PATENT OFFICE, 'Arbutus Biopharma Corporation (ABUS)'
BIG MISSTAKE ON MRNA PART FILING TO GET PATENT , ONE DAT $ABUS HAS PATENT NUMBER
SAID DOESN'T TAKE MORE THAN 3 DAYS
Yes it sounds like the awards could head directly to ABUS. 5% of $MRNA is a huge windfall plus future sales...
Thanks, I listened to it as it happened as well.
ModernaTX, Inc. v. Arbutus Biopharma Corporation
listen to the replay
http://www.cafc.uscourts.gov/oral-argument-recordings?title=&field_case_number_value=&field_date_value2%5Bvalue%5D%5Bdate%5D=2021-10-07
Anyone have any thoughts on the ATM being a tool to dilute $ROIV's stake to avoid takeover? Chatter seems to be picking up that $MRNA might actually be the buyer that $ABUS would be looking for?
Excellent insight, Thanks
Not enough. In the court filings, it was stated that both parties spoke to each other in an attempt to settle it before the hearing and that was unsuccessful. It is likely that Moderna offered very low and Arbutus rejected it. Good for Arbutus, because if it wins 069 and the other patent, it can then ask for more. If it goes to Court (And Arbutus does hypothetically win on the patent dispute with PTAB) then Moderna is in even worse shape. IMO Moderna should have settled before the hearing, to settle after it's gonna cost them more. Because then Arbutus May have two favorable patents won, and they could ask for as much as they like in royalties.
MRNA will almost certainly agree to pay a modest royalty on US sales sales of Spikevax; the question is how modest is modest?
In essence, I watched the video about the case. Bottom-line it's favorable for Arbutus Biopharma. There are two paths now:
1.) Rubber stamp of approval for protecting Arbutus' patent which could take 3 to 10 days
2.) Few weeks to few months for all 3 judges to favor Arbutus writing their opinion on why they chose to do so and what they think about the case itself.
As far reversal, based on what I heard on the hearing Moderna had not other valid argument other than " They are going to sue us" if you rule in their favor. I would have hoped they had a way to argue on the merits of the LNP technology but likely they know they stole IP.
Also all 3 judges used to be proponents of protecting patents and siding with patent companies on IP. It's very unlikely that Moderna will will on this appeal. That's just my opinion on it.
CHATTER ONE PER SECOND https://finviz.com/quote.ashx?t=abus&ty=c&ta=1&p=d
THANK YOU HEARING VIDEO 'Arbutus Biopharma Corporation (ABUS)'
RE;
Watch Live:
ALL TIME HIGH ABOUT $31.50 Arbutus Biopharma Corporation (ABUS)'
'Arbutus Biopharma Corporation (ABUS)'
A lot of talking heads talking about PFE
Pfizer and BioNTech are less likely targets because of BioNTech's ongoing relationship with Genevant.
July 10, 2018 01:00 AM Eastern Daylight Time
MAINZ, Germany & CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--BioNTech AG and Genevant Sciences today announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs. Genevant is eligible to receive significant commercial milestones for the oncology licenses.
Also, Genevant appears in all BioNTech PR's
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.
In case you did not catch this?
Wow now that's impressive! Wouldn't be too much to ask for at all with me! LOL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |